Theravance Biopharma buy klostergang
Start price
01.12.18
/
50%
€25.26
Target price
04.11.21
€34.28
Performance (%)
-41.40%
End price
17.06.21
€14.80
Summary
This prediction ended on 17.06.21 with a price of €14.80. The BUY prediction by klostergang for Theravance Biopharma performed very badly with a performance of -41.40%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Theravance Biopharma | -4.698% | -4.698% | -19.774% | -40.833% |
| iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
| iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
| iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
| iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by klostergang for this prediction
In the thread Theravance Biopharma diskutieren
klostergang stimmt der Buy-Einschätzung von marge zu
klostergang stimmt am 01.12.2018 der Buy-Einschätzung von marge mit dem Kursziel 55$ zu.
Überschrift: TBPH: Revefenacin for Chronic Obstructive Pulmonary disease [COPD]